Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes

Clinical Therapeutics

Volumn 38, Issue 3, 2016, Pages 582-594

  Brunton, Stephen ^a   Davidson, Jaime A ^b  

^a Primary Care Metabolic Group   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

delayed action preparations; exenatide; pharmacology; type 2 diabetes

Indexed keywords

EXENDIN 4; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; MICROSPHERE; PIOGLITAZONE; PLACEBO; POLYGLACTIN; SITAGLIPTIN; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; GLUCOSE BLOOD LEVEL; PEPTIDE; VENOM;

ARTHRALGIA; ARTICLE; CARDIOVASCULAR RISK; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DYSPEPSIA; ERYTHEMA; FATIGUE; FOREIGN BODY REACTION; HEADACHE; HUMAN; INJECTION SITE REACTION; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT PREFERENCE; PRURITUS; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; CARDIOVASCULAR DISEASES; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; RISK FACTOR;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; RISK FACTORS; VENOMS;

EID: 84960809146     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.01.014     Document Type: Article

References (55)

1. American Diabetes Association. Statistics About Diabetes. 2014. http://www.diabetes.org/diabetes-basics/statistics/. Accessed August 8, 2014.
2. Centers for Disease Control and Prevention National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States 2014 US Department of Health and Human Services Atlanta, GA
3. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, and et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
4. I.M. Stratton, A.I. Adler, H.A. Neil, and et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study BMJ 321 2000 405 412
5. R.A. Defronzo Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
6. A.J. Garber, M.J. Abrahamson, J.I. Barzilay, and et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement Endocr Pract 19 2013 1 48
7. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, and et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 2015 140 149
8. S.S. Grossman Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes Adv Ther 31 2014 247 263
9. Byetta (exenatide) injection [US prescribing information] 2015 AstraZeneca Pharmaceuticals LP Wilmington, DE
10. Bydureon (exenatide extended-release for injectable suspension) [US prescribing information] 2015 AstraZeneca Pharmaceuticals LP Wilmington, DE
11. J.A. Lovshin, and D.J. Drucker Incretin-based therapies for type 2 diabetes mellitus Nat Rev Endocrinol 5 2009 262 269
12. S. Bhavsar, S. Mudaliar, and A. Cherrington Evolution of exenatide as a diabetes therapeutic Curr Diabetes Rev 9 2013 161 193
13. M.B. DeYoung, L. MacConell, V. Sarin, and et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes Diabetes Technol Ther 13 2011 1145 1154
14. M. Fineman, S. Flanagan, K. Taylor, and et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing Clin Pharmacokinet 50 2011 65 74
15. K. Iwamoto, R. Nasu, A. Yamamura, and et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes Endocr J 56 2009 951 962
16. Y.M. Cui, X.H. Guo, D.M. Zhang, and et al. Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus J Diabetes 5 2013 127 135
17. R.M. Bergenstal, C. Wysham, L. Macconell, and et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial Lancet 376 2010 431 439
18. T. Blevins, J. Pullman, J. Malloy, and et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Metab 96 2011 1301 1310
19. J.B. Buse, M. Nauck, T. Forst, and et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study Lancet 381 2013 117 124
20. M. Diamant, L. Van Gaal, S. Stranks, and et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial Lancet 375 2010 2234 2243
21. D.J. Drucker, J.B. Buse, K. Taylor, and et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
22. D. Russell-Jones, R.M. Cuddihy, M. Hanefeld, and et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study Diabetes Care 35 2012 252 258
23. M. Diamant, L. Van Gaal, B. Guerci, and et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial Lancet Diabetes Endocrinol 2 2014 464 473
24. R.R. Henry, E.J. Klein, J. Malloy, and et al. DURATION-1 extension: Efficacy and tolerability of exenatide once weekly (QW) over 6 years in patients with T2DM Diabetes 63 2014 A212 A343
25. M. Grimm, J. Han, C. Weaver, and et al. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: An integrated analysis of the DURATION trials Postgrad Med 125 2013 47 57
26. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, and et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
27. K. Hirata, S. Kume, S. Araki, and et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model Biochem Biophys Res Commun 380 2009 44 49
28. T. Okerson, and R.J. Chilton The cardiovascular effects of GLP-1 receptor agonists Cardiovasc Ther 30 2012 e146 e155
29. J.M. Barragan, R.E. Rodriguez, J. Eng, and E. Blazquez Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats Regul Pept 67 1996 63 68
30. K.D. Laugero, A.H. Stonehouse, S. Guss, and et al. Exenatide improves hypertension in a rat model of the metabolic syndrome Metab Syndr Relat Disord 7 2009 327 334
31. M. Yu, C. Moreno, K.M. Hoagland, and et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats J Hypertens 21 2003 1125 1135
32. H. Yamamoto, C.E. Lee, J.N. Marcus, and et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons J Clin Invest 110 2002 43 52
33. Q. Liu, L. Adams, A. Broyde, and et al. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats Cardiovasc Diabetol 9 2010 32
34. M. Diamant, L. Van Gaal, S. Stranks, and et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks Diabetes Care 35 2012 683 689
35. R.J. Chilton, L. MacConell, J. Han, and S.P. Marso Characterization of heart rate increases with glucagon-like peptide-1 agonist therapy Circulation 128 Suppl 22 2013 A16290
36. J.B. Buse, D.J. Drucker, K.L. Taylor, and et al. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care 33 2010 1255 1261
37. C. Ellero, J. Han, S. Bhavsar, and et al. Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: A retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects Diabet Med 27 2010 1168 1173
38. M.S. Fineman, L.Z. Shen, K. Taylor, and et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes Diabetes Metab Res Rev 20 2004 411 417
39. M. Shomali Optimizing the care of patients with type 2 diabetes using incretin-based therapy: Focus on GLP-1 receptor agonists Clin Diabetes 32 2014 32 43
40. J.C. Garbutt, H.R. Kranzler, S.S. O'Malley, and et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial JAMA 293 2005 1617 1625
41. J.M. Kane, M. Eerdekens, J.P. Lindenmayer, and et al. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic Am J Psychiatry 160 2003 1125 1132
42. Y. Bloch, S. Mendlovic, S. Strupinsky, and et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: Do they hurt? J Clin Psychiatry 62 2001 855 859
43. M.S. Fineman, K.F. Mace, M. Diamant, and et al. Clinical relevance of anti-exenatide antibodies: Safety, efficacy and cross-reactivity with long-term treatment Diabetes Obes Metab 14 2012 546 554
44. S.E. Fineberg, J.A. Galloway, N.S. Fineberg, and J. Goldman Effects of species of origin, purification levels, and formulation on insulin immunogenicity Diabetes 32 1983 592 599
45. A.R. Meloni, M.B. DeYoung, C. Lowe, and D.G. Parkes GLP-1 receptor activated insulin secretion from pancreatic beta-cells: mechanism and glucose dependence Diabetes Obes Metab 15 2013 15 27
46. R. Garg, W. Chen, and M. Pendergrass Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis Diabetes Care 33 2010 2349 2354
47. C. Nitsche, S. Maertin, J. Scheiber, and et al. Drug-induced pancreatitis Curr Gastroenterol Rep 14 2012 131 138
48. M. Pladevall, L.K. Williams, L.A. Potts, and et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes Diabetes Care 27 2004 2800 2805
49. P.M. Ho, J.S. Rumsfeld, F.A. Masoudi, and et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus Arch Intern Med 166 2006 1836 1841
50. L.A. Donnelly, A.D. Morris, and J.M. Evans DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes QJM 100 2007 345 350
51. S.S. Johnston, H. Nguyen, E. Felber, and et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States Adv Ther 31 2014 1119 1133
52. A.B. Hauber, H. Nguyen, J. Posner, and et al. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes Curr Med Res Opin 32 2016 251 262
53. S.S. Johnston, H. Nguyen, K. Cappell, and et al. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States J Med Econ 18 2015 666 677
54. B. Wang, J.A. Roth, H. Nguyen, and et al. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States PLoS One 10 2015 e0121915
55. A.J. Garber, M.J. Abrahamson, J.I. Barzilay, and et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement - executive summary Endocr Pract 19 2013 536 557